A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid
Phase 2/3
Completed
NCT04206553
| Condition | Bullous Pemphigoid |
|---|
| Phase | Phase 2/3 |
|---|
| Sponsor | Regeneron Pharmaceuticals |
|---|
| Status | Completed |
|---|
| Enrollment | 106 participants |
|---|
| Interventions | dupilumab, Matching Placebo, Oral corticosteroids (OCS) |
|---|
| Start date | Oct 28, 2020 |
|---|
| Completion date | Jul 12, 2024 |
|---|
| Results posted | Mar 6, 2026 |
|---|
Summary
The main purpose of this study is to investigate whether dupilumab is effective and safe for the treatment of bullous pemphigoid. Dupilumab is a type of drug called a "monoclonal antibody". An antibody is a special kind of protein that the immune (defense) system normally makes to fight bacteria and viruses. Bullous pemphigoid is an autoimmune subepidermal blistering disease, predominately affecting the elderly (typical onset after age 60). The study is looking at several other research questions, including: * Side effects that may be experienced by people taking dupilumab * How dupilumab works in the body and affects the body * How dupilumab affects quality of life * How much dupilumab is present in the blood * To see if dupilumab works to wean the patient off oral corticosteroids
Percent of Participants Achieving Sustained Remission at Week 36
At Week 36 · Estimated Percentage of Participants
| Placebo | 4.0 Estimated Percentage of Participants |
|---|
| Dupilumab Q2W | 18.2 Estimated Percentage of Participants |
|---|
| p-value | 0.0250 |
|---|
| Risk Difference (RD) | 14.2 (95% CI 1.97–27.74) |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.